IBRX News and Press, ImmunityBio Inc. From 03/05/24

All participants in the Phase 1 pilot study experienced a marked decrease in the burden of infection, and the procedures were found to be safe and well tolerated N-803 is being studied in three other HIV cure-related clinical trials ImmunityBio ( NASDAQ: IBRX ), a clinical-stage...

SilverBow Resorces Inc. (SBOW) is expected to report $2.36 for Q4 2023 FAT Brands Inc. Class B Common Stock (FATBB) is expected to report for quarter end 2023-12-31 Ecovyst Inc. (ECVT) is expected to report $0.2 for Q4 2023 MYR Group Inc. (MYRG) is expected to report $1.41 for Q4 2023...

2024-02-23 17:39:49 ET Gainers: Sizzle Acquisition  ( SZZL ) +12% . ImmunityBio ( IBRX ) +6% . E.W. Scripps   ( SSP ) +5% . Outset Medical ( OM ) +5% . BigCommerce Holdings. ( BIGC ) +5% . Losers: EverQuote...

The first 20 participants have been enrolled in an important national, multicenter trial to test whether ImmunityBio’s Nant Cancer Vaccine (NCV) comprising a tri-valent Adenovirus (Tri-Ad5) in combination with the company’s IL-15 superagonist N-803 could potentially prevent colon an...

Vimeo Inc. (VMEO) is expected to report $-0.01 for Q4 2023 Heineken N.V ADR (HEINY) is expected to report for Q4 2023 American States Water Company (AWR) is expected to report $0.53 for Q4 2023 NextPlay Technologies Inc. (NXTP) is expected to report for Q3 2024 Inseego Corp. (INSG...

Owens Corning Inc New (OC) is expected to report $2.82 for Q4 2023 Getty Realty Corporation (GTY) is expected to report $0.56 for Q4 2023 Bion Environmental Technologies Inc. (BNET) is expected to report for Q2 2024 Nexien BioPharma Inc (NXEN) is expected to report for Q2 2024 Ayt...

2024-02-11 02:41:56 ET Summary Pre-PDUFA positioning is a good opportunity to buy ImmunityBio stock at a low price. Multiple catalysts could drive the stock price higher over the next 24 months. ImmunityBio has the potential to become a big pharma company rather than being sol...

Patient Reported Outcomes (PROs) based on a May 16, 2022 data cutoff in the QUILT 3.032 trial indicate stability of physical function and global health in patients who completed PRO questionnaires and reached month 24 on-study Overall, participants with complete responses (CRs) to combination...

2024-01-29 15:13:38 ET More on Karuna Therapeutics Karuna Therapeutics: Rewiring The Schizophrenia Paradigm - A Novel Leap Beyond Dopamine Karuna Therapeutics, Inc. (KRTX) Q3 2023 Earnings Conference Call Transcript M&A activity expected to pick up in 2024, banke...

2024-01-25 14:20:00 ET Summary With a lead asset in advanced Phase-III testing, CG Oncology, which debuts Thursday on the NASDAQ, is one of the year’s most highly anticipated IPOs. The company’s lead drug targets a sizable addressable market (NMIBC) where there is an...